Shots:
The US FDA has accepted sBLA & granted priority review to Hympavzi for the treatment of pts (≥6yrs.) with hemophilia A or B with inhibitors & in pts (6-11yrs.) with hemophilia A or B without inhibitors (PDUFA: Q2’26)
sBLA for Hympavzi (SC, QW) in adults & adolescents was supported by data from the inhibitor…
